Opinion|Videos|March 20, 2025
Clinical Perspectives on Early Use of RAD-ENZ
Panelists discuss how early implementation of RAD-ENZ combination therapy requires careful consideration of patient characteristics, disease burden, and long-term treatment planning while potentially offering the greatest benefit when initiated before significant disease progression occurs.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- What are your clinical perspectives on using this combination therapy upfront and early in the disease stage?
- How can the findings from PEACE-3 influence the design of future trials, particularly with respect to patient selection, end points, and safety monitoring?
Advertisement
Related to this article
OpenFlo incorporates a design that modifies key mechanical features of conventional Foley catheters.
Study design discussions can help patients weigh personalized marketing claims, according to Jean Cunningham, PharmD, BCPS.
VIR-5500 is a PSMA-targeted PRO-XTEN dual-masked T-cell engager entering phase 3 development for prostate cancer.
Marie-Pier St-Laurent, MD, FRCSC, explains how NeoBLAST combines imaging, TURBT, and ctDNA to identify candidates for bladder-sparing surveillance.
Bladder symptoms during IVF often reflect hormonal and pelvic floor changes, not infection, according to Aleece Fosnight, MSPAS, PA-C.
A national survey found US hospitals expanded CAUTI prevention over 20 years, but use of key catheter-removal strategies remains variable.
Rezūm improved symptoms and quality of life at 1 year vs combination pharmacotherapy in sexually active men with BPO while preserving sexual function.
Sri Sivalingam, MD, discusses how suction-based technologies are improving stone clearance and raising expectations for ureteroscopic stone treatment.
Advertisement
Advertisement